Drug Target Review

SEPTEMBER 1, 2023

During this expansion, cells can also be genetically engineered – for instance with a chimeric receptor such as Triumvira’s proprietary T cell antigen coupler (TAC) – to equip immune cells with additional properties that will increase their therapeutic activity. Author Bio: Dr Andreas Bader Dr Andreas Bader joined Triumvira in 2018.

Therapies 105

Therapies Engineering Production Clinical Trials 105

Drug Target Review

AUGUST 29, 2024

By simultaneously deleting CD5 and expressing a CD5-targeting CAR into engineered patient T cells, VIPER-101 offers a novel approach for treating T-cell lymphoma. Can you explain the key features and benefits of the Senza5 platform developed by Vittoria Biotherapeutics?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Broad Institute

SEPTEMBER 15, 2023

TBD By lcopelan@broadinstitute.org September 15, 2023 Alexander Lin School of Engineering and Applied Sciences, Harvard University MIA About Current Schedule Video Playlist Resources All talks Contact us MIA Talks Search - Any - Fall 2023 Spring 2023 Spring 2024 Fall 2022 Spring 2022 Fall 2021 Spring 2021 Fall 2020 Spring 2020 Fall 2019 Spring 2019 (..)

Engineering 40

Engineering Science 40

Broad Institute

AUGUST 31, 2023

Theoretical background regarding GANs and Causal GAN By lcopelan@broadinstitute.org August 31, 2023 Yazdan Zinati McGill University, Electrical and Computer Engineering, Montréal, Canada MIA About Current Schedule Video Playlist Resources All talks Contact us MIA Talks Search - Any - Spring 2023 Fall 2022 Spring 2022 Fall 2021 Spring 2021 Fall 2020 (..)

Engineering 40

Engineering 40

The Pharma Data

MARCH 13, 2021

Fei-Fei Li studied Physics, Computer Science and Engineering at Princeton University, where she gained a B.A. She then received a Master in Electrical Engineering from the California Institute of Technology in 2003, and a PhD in Electrical Engineering in 2005. United States. Li is a U.S. in Business Administration.

International 52

International Engineering Science Marketing 52

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. When the company launched an IPO in late 2018, its valuation was $7 billion, which at the time was a record biotech IPO.

Marketing 52

Marketing Engineering Therapies Disease 52

Perficient: Drug Development

SEPTEMBER 11, 2024

Example: Google’s Site Reliability Engineering (SRE) teams have the autonomy to make decisions and are encouraged to innovate. Encouraging Autonomy Give teams the autonomy to make decisions about their work, fostering a sense of ownership and responsibility. Humble, J., & Kim, G. ” Atlassian Blog.

Engineering 52

Engineering Science Production 52

Codon

NOVEMBER 3, 2024

Testing the engineered cells against four common drugs, I found that the M. In 2018, GlaxoSmithKline (GSK) piloted a new vaccine that may outmatch the BCG vaccine in treating pulmonary TB in adults. By inserting the gene into a harmless, related species called M.

Vaccine 96

Vaccine Trials Therapies Treatment 96

Drug Target Review

SEPTEMBER 26, 2023

The CiPA initiative aims to engineer an assay to assess the proarrhythmic potential of new drugs with improved specificity compared to current methods. 2018 Mar;17(3):167–81. 2018 Dec 11;94(10):390–411. 2018;(136):56573. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, et al. Nat Rev Drug Discov.

Drugs 111

Drugs FDA Disease Animal Testing 111

NIH Director's Blog: Drug Discovery

MAY 9, 2019

Among those taking on this ambitious challenge is a recipient of a 2018 NIH Director’s New Innovator Award, Srivatsan Raman of the University of Wisconsin-Madison. 2] Engineering an allosteric transcription factor to respond to new ligands. Jarvis LM, Chemical & Engineering News. Trends Biochem Sci. 2008 Sep;33(9):420-425.

Engineering 52

Engineering Regulations Science Therapies 52

Drug Target Review

DECEMBER 28, 2023

Researchers believe there is potential for its use in other modalities such as clonal neoantigen cancer vaccines (mRNA vaccines or other vaccine platforms using highly immunogenic clonal neoantigens to improve efficacy) and T-cell receptor (TCR) therapy, wherein T cells could be engineered with receptors that target shared neoantigens.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Codon

JUNE 18, 2024

When these engineered cells are then placed into a mouse, one can use ultrasound to “hear” the cells as they move around. It was only once gas vesicles were fished from the natural world and engineered in the laboratory that the next great leap in their evolution happened. coli and human cells. But light has limits.

Engineering 66

Engineering Laboratories International Clinical Trials 66

Drug Target Review

JULY 13, 2023

Dewpoint Therapeutics, a platform drug discovery company founded in 2018, has been at the forefront of this exciting field. He was an undergraduate at Cornell University in the Department of Biological and Agricultural Engineering. He holds a PhD in Biology from The Rockefeller University and an MD from Weill Cornell Medical College.

Disease 98

Disease Small Molecule Cell Biology Drugs 98

The Pharma Data

MARCH 4, 2021

In 2014, she was appointed Chief Operating Officer and member of the Group’s Executive Committee, and she has led from the end of 2018 all the IT teams with the group’s technological transformation as her mission.

Medical Schools 52

Medical Schools Hospitals International Engineering 52

The Pharma Data

OCTOBER 26, 2020

Based in Flowood, MS , Zavation designs, engineers, and manufactures a portfolio of spinal hardware and biologics covering key areas including cervical, thoracolumbar, interbody fusion, interventional spine, and minimally invasive surgery. ” . ABOUT ZAVATION MEDICAL PRODUCTS, LLC. .

Production 52

Production Doctors Engineering 52

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories. About the ISPE Facility of the Year Awards Program.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Engineering 52

Codon

JULY 14, 2024

5 An added benefit of PSCs is that they are amenable to genetic modifications, making it possible to engineer blood cells with specific properties. Cultured red blood cells can also be genetically engineered to act as synthetic sensors that detect circulating molecules inside the body. Science Robotics (2018).

Production 140

Production Clinical Trials Trials Therapies 140

Codon

SEPTEMBER 8, 2024

dropped drastically, from around 750 offenses per 100,000 people in 1990 to under 400 in 2018. The prior day, engineers working on the rocket had sent charts to NASA with evidence that it was not safe to launch due to the forecast of cold weather and the way that o-rings (circular seals used in the shuttle) responded to cold temperatures.

Production 111

Production Engineering Science Research 111

The Pharma Data

OCTOBER 21, 2020

” Kaltenbach joined BD as president of the Life Sciences segment in May 2018 , after serving as senior vice president of Agilent and president of their Life Sciences and Applied Markets Group, where he was directly responsible for the majority of Agilent’s instrumentation and software portfolio.

Science 52

Science Engineering Laboratories Therapies 52

Drug Target Review

JANUARY 22, 2024

When these are identified, it could be possible to produce organoids and other engineered tissues in larger volumes with higher degrees of consistency and fidelity to scale up the technology. 2018 September [2024 January 15]; 293(36):13795-804. This study was published in Molecular Cell. References 1 Drouin J, Mayran A.

DNA 59

DNA Engineering Hospitals Research 59

The Pharma Data

DECEMBER 15, 2020

The researchers studied data from 332 drivers age 16 to 19 who were diagnosed with a concussion, seen between late January and late August 2018 at CHOP’s specialty care concussion program. On average, the teens were seen 12 days after being injured. Their data was included in the Minds Matter Concussion Program registry. .

Nurses 52

Nurses Hospitals Engineering Research 52

Perficient: Drug Development

OCTOBER 3, 2023

She joined the company in 2018 after serving as vice president of accounting and controller at Isle of Capri Casinos, Inc., He has a bachelor’s degree in mechanical engineering from Andhra University, India. and in senior finance positions at Smurfit-Stone Container Corporation, Argosy Gaming Company, and Arthur Andersen LLP.

Engineering 52

Engineering Marketing Production 52

The Pharma Data

NOVEMBER 22, 2021

State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem Sustainable environmental engineering aligned to Company’s zero carbon future. This enhancement moves AstraZeneca well above the current assiduity average success rate of 14 in the 2018-2020 timeframe.4.

Molecular Biology 52

Molecular Biology Laboratories Engineering Hospitals 52

The Pharma Data

OCTOBER 18, 2020

About TG4001 TG4001 is an investigational therapeutic vaccine based on a non-propagative, highly attenuated Vaccinia vector (MVA), which is engineered to express HPV16 antigens (E6 & E7) and an adjuvant (IL-2). In this heterogenous group of malignancies, overall response rates are around 10–15% [2-6].

Vaccine 40

Vaccine Trials Virus Treatment 40

National Institute on Drug Abuse: Nora's Blog

SEPTEMBER 25, 2024

A new analysis by the National Academies of Sciences, Engineering, and Medicine found that early legalization efforts have prioritized economic outcomes over public health. Trends in Cannabis Use Among Older Adults in the United States, 2015-2018. Journal of Adolescent Health. 2020; 66(2):247-254. Han BH, Palamar JJ.

Drugs 106

Drugs Production Science Marketing 106

The Pharma Data

JANUARY 14, 2021

More recently, he was a member of the Cohasset Board of Health between 2015 and 2018. Additionally, Dr. Dickstein has greatly enjoyed contributing civically to his community over the years. Marquis® publications may be visited at the official Marquis Who’s Who® website at www.marquiswhoswho.com. # # #. Source link.

Laboratories 52

Laboratories Clinical Research Hospitals Pharmaceuticals 52

The Pharma Data

DECEMBER 13, 2020

Margetuximab is an investigational, Fc-engineered, monoclonal antibody targeting HER2. “We will continue to work closely with the Agency to potentially bring margetuximab as a treatment option to patients with HER2-positive metastatic breast cancer.”.

FDA 52

FDA Biosimilars Clinical Trials Licensing 52

The Pharma Data

DECEMBER 1, 2020

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. About Innate Pharma: Innate Pharma S.A. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

Cell Biology 52

Cell Biology Clinical Trials Production Licensing 52

The Pharma Data

JANUARY 17, 2021

John received his degrees in medicine and surgery from the University of Melbourne in Australia and in 2018 was recognized as an Officer of the Order of Australia for his distinguished service to medical research. Before this, he held various positions at Duke University Medical Center. ” About Evox Therapeutics.

Science 40

Science Engineering Disease Laboratories 40

Drug Target Review

JUNE 21, 2023

19,20 Mutations are introduced across the genome of these cells through gene-trap mutagenesis and the resulting phenotypes can be monitored with fluorescent markers in both wildtype cells and cells with an engineered disease mutations. 2018; 39: 1739– 1751. 2018 Aug 15;13(1):140. PMID: 28777930; PMCID: PMC5544383.

Disease 111

Disease Clinical Trials Therapies Science 111

The Pharma Data

JULY 22, 2021

The two companies had previously announced in 2018 a separate research collaboration and license agreement for the discovery and development of drug candidates using Arvinas’ PROTAC technology. Terms of the Collaboration. The agreement is a worldwide co-development and co-commercialization collaboration.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 26, 2020

On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

Pharmaceuticals 40

Pharmaceuticals Engineering Disease Pharmaceutical Companies 40

The Pharma Data

DECEMBER 9, 2020

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda.

Licensing 40

Licensing Licensing Pharmaceutical Companies Engineering 40

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to Aktana, Daveynis served as vice president of engineering at Verint and held prior leadership roles at Capsilon, Quantros, HP, and Kodak.

Small Molecule 52

Small Molecule Engineering Clinical Development Pharmaceuticals 52

New Drug Approvals

SEPTEMBER 13, 2024

30 January 2018. Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ (March 2018). McHugh KL, Kelly JP (2018). Bailey SJ, Husbands SM (June 2018). Chavkin C (August 2018). December 2018). HRMS (APCI+): calculated for [M+H]+ : 260.0717, found: 260.0716. 1 (2): 4–16. . 1 (2): 4–16. PMC 4871611. PMID 27213169.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

The Pharma Data

DECEMBER 2, 2020

Kazumi was also a co-founder and CEO of Mitobridge, a start-up company developing mitochondrial drugs for the treatment of muscle and kidney diseases, until its acquisition by Astellas Pharma in 2018. Enthera’s discovery engine and assets are protected by a broad portfolio of patents. For more information, visit [link].

Pharmaceuticals 52

Pharmaceuticals Synthetic Chemistry RNA Disease 52

The Pharma Data

OCTOBER 26, 2020

TG4001 is an investigational therapeutic vaccine based on a non-propagative, highly attenuated Vaccinia vector (MVA), which is engineered to express HPV16 antigens (E6 & E7) and an adjuvant (IL-2). More information on the trial is available on clinicaltrials.gov. About TG4001. . [15].

Vaccine 40

Vaccine Trials Treatment Virus 40